Discover the groundbreaking patent granted to Spectrum Pharmaceuticals Inc for a quinazoline compound, its crystalline forms, and hydrochloride salts. Learn about the innovative preparation method, ...

The Business Journal’s annual listing of the largest local players in the pharmaceutical industry shows a sector that remains ...

Spectrum Pharmaceuticals Inc. (SPPI) popped Thursday after the company announced that it was selling its marketed portfolio of seven Food and Drug Administration-approved products to Acrotech ...

Now let's look at TheStreet Ratings' take on this stock. TheStreet Ratings team rates SPECTRUM PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about ...

Assertio's acquisition of Spectrum Pharmaceuticals, Inc. and Spectrum's injection asset, Rolvedon, was less valuable than Assertio had represented to investors; (iii) accordingly, Assertio had ...

Assertio's acquisition of Spectrum Pharmaceuticals, Inc. and Spectrum's injection asset, Rolvedon, was less valuable than Assertio had represented to investors; (iii) accordingly, Assertio had ...

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company ... The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that ...

Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net ...

Mirum Pharmaceuticals, Inc., a biopharmaceutical company ... including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which ...

Inc. MNMD have skyrocketed 154% in the past three months against the industry’s decline of 4.2%. The company is progressing ...

Canadabis Capital, and its shareholdings in Stigma Grow a leading innovator in the Canadian cannabis industry, is thrilled to ...

Acurx Pharmaceuticals, Inc. is scheduled to present on April 8th ... develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ ...